WO1995007020A1 - EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE - Google Patents

EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE Download PDF

Info

Publication number
WO1995007020A1
WO1995007020A1 PCT/US1993/008476 US9308476W WO9507020A1 WO 1995007020 A1 WO1995007020 A1 WO 1995007020A1 US 9308476 W US9308476 W US 9308476W WO 9507020 A1 WO9507020 A1 WO 9507020A1
Authority
WO
WIPO (PCT)
Prior art keywords
ignt
nucleic acid
human
active fragment
acid molecule
Prior art date
Application number
PCT/US1993/008476
Other languages
English (en)
Inventor
Minoru Fukuda
Marti F. A. Bierhuizen
Original Assignee
La Jolla Cancer Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Cancer Research Foundation filed Critical La Jolla Cancer Research Foundation
Priority to PCT/US1993/008476 priority Critical patent/WO1995007020A1/fr
Publication of WO1995007020A1 publication Critical patent/WO1995007020A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C12N9/107—1,4-Alpha-glucan branching enzyme (2.4.1.18)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Glycoconjugates are major components of the outer surface of mammalian cells. During mammalian development, the carbohydrate structures of these glycoconjugates change dramatically. In many cases, specific sets of carbohydrates are characteristic for particular stages of differentiation. Where these specific carbohydrates are recognized by specific antibodies, the carbohydrate structures are useful as differentiation antigens (Feizi, Nature 314:51-55, (1985); Fukuda et al., J. Biol. Chem.. 260:6623-6631 (1985), each of which is incorporated herein by reference) . In the mature organism, expression of distinct carbohydrates ultimately is restricted to specific cell types and aberrations in the specific cell surface carbohydrates often are associated with malignant transformation of the cells (Hakomori, Ann. Rev. Immunol.. 2:103-126 (1984)). Although the functional significance of alterations in cell surface carbohydrates during cell differentiation and in malignancy is not completely understood, several reports suggest that these molecules are involved in the modulation of adhesive processes.
  • each glycosyltransferase catalyzes a single enzymatic reaction to form a specific linkage.
  • One notable exception is the Lewis fucosyltransferase, which can synthesize both ⁇ l,3 and ⁇ l,4 linkages (Prieels et al., J. Biol. Chem. 256:10456-10463 (1981); Kukowska-Latallo et al.. Genes & Devel. 4:1288-1303 (1990), each of which is incorporated herein by reference).
  • a specific linkage usually is associated with the formation of specific oligosaccharides, which also may contain other linkages formed in conjunction with the action of other glycosyltransferases.
  • oligosaccharides on the cell surface is the result of the coordinate expression of one or more glycosyltransferase genes responsible for synthesis of the oligosaccharide linkages.
  • glycosyltransferase genes responsible for synthesis of the oligosaccharide linkages.
  • cDNAs encoding approximately a dozen different glycosyltransferases have been isolated (Paulson and Colley, J. Biol. Chem.. 264:17615-17618 (1989); Schachter, Curr. Qpin. Struct. Biol.. 1:755-765 (1991); Joziasse, Glvcobiolo ⁇ v 2:271-277 (1992)).
  • the present invention provides an isolated nucleic acid molecule encoding both soluble and membrane- bound forms of human ⁇ -l , 6-N-acetylglucosaminyltransferase, the I-branching enzyme (IGnT).
  • the invention also provides vectors containing an isolated nucleic acid molecule encoding human IGnT as well as recombinant host cells transformed with such vectors.
  • the invention further provides a method of preparing and purifying soluble human IGnT.
  • the present invention also provides antisense oligonucleotides complementary to a nucleic acid molecule encoding a human IGnT, antibodies directed to a human IGnT, pharmaceutical compositions related to human IGnT and transgenic nonhuman mammals that express DNA sequences encoding normal or mutant human IGnT or that express antisense oligonucleotides complementary to a DNA sequence encoding normal or mutant human IGnT. Also provided are methods for regulating the expression of human IGnT and for modifying a biological function mediated by the regulatory activity of IGnT. Methods for detecting the presence of linear polylactosaminoglycans expressing i antigenic determinants on the cell surface also are provided.
  • Figure 1 depicts the structure and biosynthesis of i and I antigens.
  • the i antigen is expressed by a linear polylactosaminoglycan and is converted into the I antigen by the stepwise addition of GlcNAc ⁇ l-6 and Gal ⁇ l-*4 residues to produce poly-N-acetyllactosamines (also called polylactosaminoglycans) .
  • Figure 2 depicts the domain structures and homologous regions of IGnT and C2GnT (core 2 ⁇ -l , 6-N- acetylglucosaminyltransferase) .
  • Alignment of the two ⁇ - 1 , 6-N-acetylglucosaminyltransferases cloned to date reveals a 126 amino acid sequence having 60% sequence identity, a 33 (or 32) amino acid sequence having greater than 59% identity and a 22 amino acid sequence having 59% identity (hatched boxes). Closed boxes indicate the signal anchor domain and "Y" indicates potential N-glycosylation sites.
  • Figure 3 indicates regions in IGnT and C2GnT that exhibit a high homology with each other.
  • I and C2 designate nucleotide sequences and I-P and C2-P designate amino acid sequences of IGnT and C2GnT, respectively. The residues are numbered with respect to the translation initiation site. Identical residues are indicated by dashes. Non-identical but similar amino acids are denoted by dots.
  • Figure 4 indicates a region of modest homology between IGnT and C2GnT.
  • I, C2, I-P and C2-P are as described in the legend to Figure 3. Residues are numbered with respect to the translation initiation site. Identical residues are indicated by dashes. Non-identical but similar amino acids are denoted by dots.
  • Figure 5 indicates a region of modest homology between IGnT and C2GnT.
  • I, C2, I-P and C2-P are as described in the legend to Figure 3.
  • the residues are numbered with respect to the translation initiation site. Identical residues are indicated by dashes. Non-identical but similar amino acids are denoted by dots.
  • Figure 6 lists the full-length DNA sequence and deduced amino acid sequence of IGnT.
  • the signal/membrane- anchoring domain is doubly underlined. Potential N- glycosylation sites are marked by asterisks. The sequences are numbered relative to the translation initiation site.
  • Figure 7 shows expression of the I antigen in cells containing pcDNAI-IGnT.
  • Cells were transfected with pcDNAI-IGnT (upper panel) or pcDNAI (lower panel) and examined by immunofluorescence staining using anti-I antigen antiserum (Ma) .
  • Cells were collected 64 hours after transfection, fixed and incubated with human anti-I serum (Ma) (1:100 dilution) followed by fluorescein isothiocyanate-conjugated goat anti-human IgM.
  • Figure 8 shows a Northern blot analysis of IGnT mRNA. Each lane contained 12 ⁇ g of poly (A) + RNA from CHO-
  • IGnT cDNA fragment representing the complete, putative lumenal domain of IGnT was used as a probe. As shown, only PA-1 cells express the IGnT mRNA. The migration positions of the RNA size markers are indicated at the left.
  • Figure 9 shows a Southern blot analysis of human genomic DNA using IGnT- and C2GnT-specific probes. Following digestion of HL-60 cell genomic DNA with either BamHI, EcoRI, Hindlll or Xbal (lanes 1-4, respectively), aliquots were separated in duplicate by agarose gel electrophoresis and transferred to nylon membranes. Blots were probed with a region of the cDNA of IGnT or C2GnT that encompasses only the putative intraluminal domain of the transferases. Mobility of molecular size markers are indicated at left (kilobases). Among the restriction enzymes employed, there is no restriction site in the coding sequence for BamHI, EcoRI and Xbal.
  • Figure 10 shows the migration in a 1% agarose gel of PCR amplification products obtained from genomic DNA template sequences.
  • the nucleotide sequences of IGnT and C2GnT were amplified by PCR and separated by agarose gel electrophoresis. The numbers at the left denote the size (in base pairs) of two molecular weight markers similar in size to the PCR products. Lanes 1 and 2, C2GnT; Lanes 3 and 4, IGnT. Lanes 1 and 3 were control lanes from PCR reactions that did not contain template genomic DNA.
  • Figure 11 shows the results of Sephadex G-50 gel filtration of 3 H-galactose-labeled polylactosaminoglycans from CHO-neo (-o-) and CHO-neo-IGnT (-•-) cells.
  • High molecular weight glycopeptides were prepared by pronase digestion of 3 H-galactose-labeled cells and applied to Sephadex G-50 columns either before (left panel) or after endo- ⁇ -galactosidase treatment (right panel).
  • Figure 12 shows the methylation analysis of 3 H- galactose labeled glycopeptides.
  • the glycopeptides as shown in the left panel of Figure 11 were subjected to methylation analysis.
  • the partially O-methylated galactose residues were separated by thin layer chromatography.
  • Figure 13 shows the distribution of labeled sites on chromosome 9 for C2GnT.
  • 241 silver grains were associated with chromosomes, 49 of which were located on chromosome 9 (20.3%).
  • Seventy-six percent of the grains located on chromosome 9 mapped to the q21.1-q22.1 region, with the greatest number appearing at the q21 band.
  • Nearly identical results were obtained for IGnT, except that an additional minor peak occurred at p23 of chromosome 6.
  • the blood group i/I antigens were the first identified alloantigens to display a dramatic change during human development.
  • the i antigen is expressed on erythrocytes of the fetus and neonate, but is replaced by the I antigen on erythrocytes in the majority of adults.
  • the I antigen is expressed throughout the preimplantation period; the i antigen is first detected in the 5-day embryo. Expression of the i antigen is more pronounced in the primary endoderm and the increase in i antigen is associated with a decrease in the I antigen.
  • the determinants that define the i and I antigens have been characterized and are carried by linear and branched polylactosaminoglycans, respectively.
  • Polylactosaminoglycans are composed of repeats of
  • N-acetyllactosamine (Gal ⁇ l-»4GlcNAc ⁇ l-»3) . Conversion of the i antigen to the I antigen is due to the expression of a ⁇ -
  • a nother example of a polylactosaminoglycan is the stage-specific embryonic antigen, SSEA-1.
  • SSEA-1 stage-specific embryonic antigen
  • This antigen is expressed at the eight-cell stage of mouse embryonic development, after which it is restricted to specific cell types during later stages of murine development.
  • the SSEA- 1 molecule is a fucosylated oligosaccharide in which fucose is attached through ⁇ l , 3-linkage to N-acetyllactosamine, forming Gal ⁇ l->4 (Fuc ⁇ l-»3)GlcNAc- * R.
  • Anti-SSEA-1 antibody or oligosaccharides containing a Gal ⁇ l-4 (Fuc ⁇ l-*3)GlcNAc terminus as inhibitors have been used to demonstrate that the SSEA-1 molecule may participate in adhesive events involved in compaction in early embryogenesis .
  • Gal ⁇ l-»3(GlcNAc ⁇ l->6)GalNAc the core 2 structure (Piller et al., J. Biol. Chem.. 263:15146-15150 (1988), which is incorporated herein by reference) ;
  • GlcNAc ⁇ l- 3(GlcNAc ⁇ l ⁇ >6)GalNAc, the core 4 structure (Brockhausen et al. Biochemistry. 24:1866-1874 (1985), which is incorporated herein by reference) and (4) GlcNAc ⁇ l-*2 ( GlcNAc ⁇ l-*6 ) Man , the N - acetylglucosaminyltransferase V product (Cummings et al., J.Biol. Chem.. 257:13421-13427 (1982), which is incorporated herein by reference) .
  • the enzymes responsible for each of these linkages share the same unique property that Mn 2 + is not required for their activity.
  • C2GnT cDNAs encoding only IGnT and core 2 ⁇ -l,6-JW- acetylglucosaminyltransferase
  • the cloned glycosyltransferases share a common type II transmembrane topology that consists of a short amino terminal cytoplasmic sequence, a signal-anchor sequence followed by a short stem region and a large carboxyl terminal catalytic domain.
  • IGnT and C2GnT have no apparent homology with other glycosyltransferases including two other N- acetylglucosaminyltransferases.
  • Comparison of the amino acid sequences of IGnT and C2GnT reveals a limited but distinct homology. As shown in Figure 2, a region of high homology is located in a sequence near the center of the presumed catalytic domain (see, also. Figure 3).
  • I branching enzyme For example, one can express I branches in sialyl Le x expressing cells, then examine whether such branches increase binding to E-selectin. One can also reduce or abolish the expression of the I branching enzyme using antisense technology or gene knock- out in transgenic mice in order to identify the critical role for I branching during embryonic development and differentiation.
  • N-acetylglucosaminyltransferase V and C2GnT have been associated with malignant transformation (Yamashita et al., J. Biol. Chem. r 259:10634-10650 (1984); Pierce and Arango, J. Biol. Chem.. 261:10772-10777 (1986); Yousefi et al., i.
  • the levels of polylactosaminoglycan synthesis are controlled by the expression of two other ⁇ - l , 6 - N - acetylglucosaminyltransferases, C2GnT, for O-glycans, and N-acetylglucosaminyltransferase V, for N-glycans .
  • C2GnT ⁇ - l , 6 - N - acetylglucosaminyltransferases
  • V N-acetylglucosaminyltransferase V
  • the present invention provides an isolated nucleic acid molecule encoding a human ⁇ -l , 6-N- acetylglucosaminyltransferase, IGnT, substantially the same as shown in Figure 6.
  • IGnT the I-branching enzyme
  • isolated nucleic acid molecule means a nucleic acid molecule that is in a form that does not occur in nature.
  • the nucleic acid sequence encoding soluble human IGnT is included within the nucleic acid sequence set forth in Figure 6 (from about nucleotide position 94 to about 1200) or any portion thereof that binds to i antigen or the I antigen.
  • a human IGnT nucleic acid can be isolated, for example, by using a natural or artificially designed antibody to IGnT to probe a human cDNA expression library. Methods for screening such a library are well known in the art (see, for example, Gougos et al., J. Biol. Chem. 265:8361 (1990) which is incorporated herein by reference). 5 DNA and cDNA molecules encoding human IGnT branching enzymes are useful for identifying and isolating complementary genomic DNA sequences, cDNA or RNA from humans or other mammalian or eukaryotic sources.
  • the invention also encompasses nucleic acid molecules that differ in sequence from the nucleic acid molecule shown in Figure 6 but produce the same phenotypic effect. These phenotypically equivalent nucleic acid molecules are referred to herein as "equivalent nucleic
  • Equivalent nucleic acids can have different nucleotide sequences but, nevertheless, encode proteins having the same amino acid sequence, due to the degeneracy of the genetic code.
  • the present invention further encompasses nucleic acid molecules characterized by
  • nucleic acid molecules that hybridize to the nucleic acid molecule of the subject invention.
  • probes can be prepared, for example, by nick translation of the nucleic
  • nucleic acid encompasses RNA as well as single and double-stranded DNA and cDNA.
  • enzyme glycosyltransferase
  • polypeptide are used herein to generally include naturally occurring allelic variants of these substances as well as man-made recombinant forms.
  • the invention also provides the isolated nucleic acid molecules operatively linked to a promoter of RNA transcription, as well as other regulatory sequences.
  • a promoter of RNA transcription indicates the nucleic acid molecule is positioned in such a manner that the promoter will direct the transcription of RNA using the nucleic acid molecule as a template.
  • Such promoters can direct transcriptional activity from a DNA-dependent RNA polymerase, which is known generally in the art as RNA polymerase, or from an RNA-dependent RNA polymerase, such as SP6, T4 and T7 RNA polymerase.
  • RNA polymerase which is known generally in the art as RNA polymerase
  • SP6, T4 and T7 RNA polymerase RNA-dependent RNA polymerase
  • a particular RNA polymerase requires a specific transcriptional start site, such as a TATA sequence or, for example, an SP6 promoter.
  • Vectors containing an appropriate promoter as well as a cloning site into which a nucleic acid molecule is inserted and operatively linked to that promoter are well known in the art (see, for example, Sambrook et al. 1989). Such vectors, which are useful for transcribing RNA in vitro or in vivo, include, for example, the pGEM series (Promega Biotec, Madison, WI).
  • the invention also provides a vector comprising an isolated nucleic acid molecule encoding a human IGnT or an active fragment thereof.
  • vectors are well known in the art and include vectors derived from a virus. such as a bacteriophage, a baculovirus or a retrovirus, and vectors derived from bacteria or a combination of bacterial and viral sequences, such as a cosmid or a plasmid (eg., pPSVEI-PyE and pZIPneo-leu) .
  • a nucleic acid molecule is inserted into a vector using any of several methods well known in the art (see, for example, Sambrook et al. 1989).
  • a nucleic acid molecule to be inserted and a vector into which the molecule is to be inserted can be treated with a restriction enzyme, which creates complementary ends on the molecule and the vector, thus allowing the ends to base pair with each other and further allowing the nucleic acid molecules to be covalently linked using, for example, a DNA ligase.
  • the nucleic acid molecule to be inserted can have ligated thereto synthetic nucleic acid linkers that correspond to a restriction site in the vector DNA. Following treatment of the DNA molecules with the appropriate restriction endonuclease, the sequences can be joined as described above.
  • a vector also can contain an oligonucleotide encoding, for example, a termination codon or other transcription or translation regulatory elements.
  • the vector also can contain an appropriate restriction site, which can be used for inserting other useful nucleic acid molecules including, but not limited to a selectable marker gene, such as the neomycin gene, which is useful for selecting stable or transient transfectants in mammalian cells; enhancer sequences and promoter sequences, which are obtained, for example, from a viral, bacterial or mammalian gene; transcription termination and RNA processing signals, which are obtained from a gene or a virus such as SV40, such sequences providing, for example, stability of a transcribed mRNA sequence; an origin of replication obtained, for example, from SV40, polyoma or E. coli , which allow for proper episomal replication; versatile multiple cloning sites; and RNA promoters such as the above- described T7 and SP6 promoters, which allow for in vitro transcription of sense and antisense
  • vectors comprising a DNA molecule encoding a human IGnT, the vectors being adapted for expression in a host cell such as a bacterial cell, a yeast cell, an insect cell, a mammalian cell and other animal cells.
  • the vectors additionally comprise regulatory elements specifically required for expression of the DNA in a particular cell, the elements being located relative to the nucleic acid molecule encoding human IGnT so as to permit expression thereof.
  • regulatory elements required for expression have been described above and include transcription and translation start sites and termination sites. Such sites permit binding, for example, of RNA polymerase and ribosome subunits.
  • a bacterial expression vector can include, for example, an RNA transcription promoter such as the lac promoter, a Shine-Delgarno sequence and an initiator AUG codon in the proper frame to allow translation of an amino acid sequence (Sambrook et al. 1989).
  • an RNA transcription promoter such as the lac promoter
  • a Shine-Delgarno sequence and an initiator AUG codon in the proper frame to allow translation of an amino acid sequence
  • an eucaryotic expression vector can include, for example, a heterologous or homologous RNA transcription promoter for RNA polymerase binding, a polyadenylation signal located downstream of the coding sequence, an AUG start codon in the appropriate frame and a termination codon to direct detachment of a ribosome following translation of the transcribed mRNA.
  • Vectors having these and other characteristics are commercially available or are assembled by one skilled in the art using well known methods described, for example, by Sambrook et al. 1989.
  • the expression vectors are useful for producing cells that express a glycosyltransferase such as IGnT.
  • the invention also provides a host cell, which contains a vector comprising a nucleic acid molecule encoding a human IGnT.
  • a host cell is a mammalian cell comprising a plasmid adapted for expression in the mammalian cell.
  • a plasmid comprises, for example, a cDNA molecule encoding a human IGnT and regulatory elements necessary for expression of the glycosyltransferase in the particular host cell.
  • Various mammalian cells are useful as host cells including, for example, mouse NIH3T3 cells, CHO cells, HeLa cells and Ltk- cells.
  • mammalian cells obtained, for example, from a primary explant culture are useful as host cells.
  • Methods for introducing an expression plasmid such as a plasmid described above are well known in the art and include, for example, various methods of transfection such as the calcium phosphate, DEAE-dextran and lipofection methods, as well as electroporation and microinjection, all of which are described in detail in Sambrook et al. 1989.
  • the present invention further provides purified human IGnT or a fragment thereof having the native enzymatic activity of human IGnT, which converts linear polylactosaminoglycan into branched poly-N- acetyllactosamines.
  • Human IGnT can consist of a membrane bound form comprising a protein of approximately 400 amino acids in length and having a molecular mass of about 45,860 daltons and a type II transmembrane topology.
  • the deduced amino acid sequence of the disclosed glycosyltransferase is set forth in Figure 6.
  • the membrane bound form of IGnT also can be an active fragment of IGnT which includes the transmembrane sequence and, therefore, is bound to a cell membrane.
  • soluble human IGnT means a biologically active fragment of the human IGnT expressed from all or a portion of the nucleic acid sequence encoding the extracellular domain of the glycosyltransferase shown in Figure 6.
  • the extracellular domain is encoded by a nucleic acid sequence comprising about nucleotides 94 to 1200 in the nucleic acid sequence of Figure 6.
  • a soluble human IGnT expressed from such a nucleic acid sequence is secreted from a cell expressing the IGnT activity and, therefore, is not present as the membrane-bound form of IGnT.
  • soluble human IGnT further includes a non-naturally occurring cleaved polypeptide, which functions as a secreted molecule and retains the ability to bind to the ligands recognized by the membrane-bound form of IGnT, such ligands including, for example, the determinants that define the i/I antigens on a cell surface.
  • human “IGnT” means a protein having an amino acid sequence that is substantially the same as the 400 amino acid sequence shown in Figure 6 or a polypeptide or a peptide encoding an active fragment of IGnT.
  • Use of the term “IGnT” is meant to include the soluble and the membrane-bound form of the human ⁇ -l , 6-N- acetylglucosaminyltransferase, the I-branching enzyme, or a biologically active fragment of the enzyme, either of which is produced by expression of an isolated nucleic acid.
  • an "active fragment,” also referred to as a “biologically active fragment,” means a portion of the IGnT amino acid sequence shown in Figure 6 that has the native activity IGnT.
  • the "native" activity of IGnT means the enzymatic activity of IGnT, which binds i/I determinants and mediates the conversion of a linear polylactosaminoglycan (i antigen) into a branched poly-N-acetyllactosamine (I antigen).
  • An active fragment of human IGnT includes a polypeptide encoded by a portion of the nucleic acid molecule shown in Figure 6, which encodes a fragment of human IGnT, such as the soluble human IGnT described above, provided that the expressed fragment has the native activity of IGnT.
  • purified means a molecule that is substantially free of contaminants normally associated with the molecule in a cell.
  • a purified membrane-bound form of IGnT is obtained using any of several methods, alone or in combination. Such methods are well known in the art and include precipitation, gel filtration, ion-exchange chromatography, reversed-phase high performance liquid chromatography and affinity chromatography. These and other methods are described in detail by Deutscher et al. (Guide to Protein Purification: Methods in Enzvmoloqy Vol. 182, (Academic Press 1990), which is incorporated herein by reference).
  • purified IGnT or an active fragment thereof can be obtained using recombinant DNA methods as described, for example, in Sambrook et al. 1989.
  • a nucleic acid encoding IGnT or an active fragment thereof is introduced into a suitable host cell, which can be induced to express the cloned nucleic acid sequence.
  • Purified IGnT or the active fragment of IGnT is recovered from the cell using the methods disclosed above.
  • a biologically active fragment of IGnT also can be produced by chemical synthesis using an Applied Biosystems. Inc. (Foster City, CA) Model 430A or 431A automatic polypeptide synthesizer and chemicals provided by the manufacturer.
  • the invention also provides antisense oligonucleotides that can bind specifically with nucleic acid sequences encoding human IGnT.
  • antisense oligonucleotides are synthesized using nucleotide analogues, which confer desirable characteristics on the oligonucleotides such as endonuclease and exonuclease resistance.
  • Antisense oligonucleotides can be designed so as to specifically bind with a preselected sequence of the nucleic acid molecule shown in Figure 6. Specific binding of an antisense oligonucleotide is useful, for example, for preventing transcription or translation of a mRNA encoding IGnT.
  • specific binding refers to the ability of a nucleic acid sequence to align with and hydrogen bond to a complementary nucleic acid sequence under relatively stringent hybridization conditions. Methods for approximating the stringency required for specific binding are well known in the art. In addition, the appropriate stringency can be empirically determined based on a calculated approximation (see, for example, Sambrook et al. 1989).
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an antisense oligonucleotide that effectively reduces expression of a human IGnT.
  • pharmaceutically acceptable carrier is meant to encompasses standard pharmaceutical carriers, such as water, phosphate buffered saline, emulsions such as an oil/water or water/oil emulsion and various types of wetting agents.
  • a pharmaceutical composition can include, for example, an oligonucleotide and a vehicle, which comprises a hydrophobic carrier molecule that facilitates introduction of the oligonucleotide through a cell membrane and specific binding with a nucleic acid encoding a human IGnT present in the cell.
  • a liposome is an example of a hydrophobic carrier molecule.
  • a pharmaceutically acceptable hydrophobic carrier also can be a structure that is recognized and bound by a particular cell surface receptor, which can be specific for a selected cell type into which one wishes to introduce the oligonucleotide. Such a structure can be part of a protein known to bind to a cell-type specific receptor such as the insulin molecule, which is useful for targeting R cells in the pancreas.
  • Antisense oligonucleotides are designed to specifically bind selected nucleic acid sequences. Specific binding can be to DNA sequences that encode IGnT mRNA, in which case transcription of the DNA sequences is inhibited, or to a sequence of the transcribed mRNA, in which case translation of the mRNA is inhibited.
  • an antisense oligonucleotide is useful as a drug to inhibit expression of IGnT in a patient, where the patient's symptoms are related to overexpression of IGnT or to aberrant expression of i antigen or I antigen.
  • the invention provides a means to therapeutically alter levels of IGnT produced in a cell by using a synthetic antisense oligonucleotide drug ("SAOD").
  • SAOD synthetic antisense oligonucleotide drug
  • the SAOD's or other antisense chemical structures designed to recognize and selectively bind to a preselected sequence of the nucleic acid molecule of Figure 6, or a mRNA transcript of the molecule or chemically modified, synthetic nucleic acid based on the molecule, are constructed so as to be complementary to the preselected sequence.
  • the designed SAOD can be stable in the blood stream of a patient following injection or in the medium of a laboratory cell culture or can be degradable after a predetermined period of time.
  • the designed SAOD also can readily traverse a cell membrane in order to enter the cytoplasm of the cell, if such traversal is desirable.
  • An SAOD having the appropriate physical and chemical properties, which allow it to pass through a cell membrane is, for example, a small, hydrophobic SAOD or an SAOD that is recognized and transported into the cell by an active cell transport mechanism. Where desirable, the designed SAOD is recognized and transported only into a preselected cell population due to targeting the designed SAOD to a cell-type specific cellular uptake mechanism, as disclosed above.
  • the SAOD is designed so as to inactivate the target nucleic acid sequence by inducing, for example, endogenous enzymes that degrade the antisense oligonucleotide-target sequence complex, such as RNAse H which degrades DNA-RNA hybrids.
  • RNAse H which degrades DNA-RNA hybrids.
  • a DNA-mRNA complex can result in inhibition of translation of the mRNA target by interfering with the binding of translation regulatory factors or ribosomes.
  • an antisense oligonucleotide can be designed to have ribozyme activity or to contain a reactive chemical group which degrades or chemically modifies a target mRNA sequence.
  • SAOD drugs are capable of such properties when directed against mRNA targets (see Cohen et al., TIPS.
  • An SAOD is as a particularly effective therapeutic agent if it can be administered in vivo and in vitro and can be used to reduce the level of IGnT in a patient having a clinical condition that may benefit from such reduced expression, such as an inflammatory response and metastatic carcinoma.
  • antibodies having specific reactivity with IGnT or an active fragment thereof are encompassed within the meaning of the term "antibody,” as used herein.
  • the antibodies of the invention can be produced by any method known in the art. For example, polyclonal and monoclonal antibodies can be produced using methods described, for example, by Harlow and Lane fAntibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988), which is incorporated herein by reference) .
  • IGnT or a fragment thereof can be used as an immunogen to generate such antibodies.
  • a soluble IGnT or soluble fragment of IGnT is useful as an immunogen.
  • Modified antibodies such as chimeric antibodies, humanized antibodies and CDR-grafted or bifunctional antibodies can be produced by methods well known to those skilled in the art and, therefore, are considered to be within the contemplated invention.
  • the antibodies can be used in the form of serum isolated from an immunized animal or the antibody can be purified from the serum or produced by a hybridoma cell line, by chemical synthesis or recombinant methods described, for example, in Harlow and Lane (1988) and in Sambrook et al. (1989).
  • the antibodies are useful for identifying, for example, cells expressing IGnT or the presence of IGnT in a biological sample obtained from a subject or for purifying IGnT from a composition containing the glycosyltransferase.
  • detection can be in vitro as in a diagnostic assay of a sample obtained from a subject or in vivo for imaging the localization of IGnT in a subject.
  • the antibodies can be administered as a pharmaceutical composition comprising the antibody and a pharmaceutically acceptable carrier.
  • Immunological procedures useful for in vitro detection of a target IGnT protein or peptide in a sample include immunoassays that employ a detectable antibody. Such immunoassays include, for example, ELISA, Pandex microfluorimetric assay, agglutination assays, flow cytometry, serum diagnostic assays and immunohistochemical staining procedures.
  • An antibody can be labelled so as to be detectable using various methods.
  • a detectable marker can be directly or indirectly attached to the antibody.
  • Useful markers include, for example, radionuclides, enzymes, fluorogens, chromogens and chemiluminescent labels.
  • the invention also provides a transgenic nonhuman mammal expressing a nucleic acid molecule encoding human IGnT or an active fragment thereof.
  • the nucleic acid molecule can encode normal human IGnT or can be mutated so that a variant human IGnT is expressed.
  • the nucleic acid molecule introduced into the transgenic nonhuman mammal can encode antisense IGnT DNA or mRNA, which hybridizes to the transgenic mammals'' own DNA or mRNA encoding IGnT, thereby preventing expression of the mammals' IGnT.
  • the invention further provides a transgenic nonhuman mammal comprising a nucleic acid molecule encoding a human IGnT and an inducible promoter which provides a means to produce variable levels of IGnT expression and, consequently, I antigen expression on a cell.
  • the invention further provides a method for modifying a biological function mediated by the regulatory activity of IGnT comprising contacting a suitable sample containing a linear polylactosaminoglycan with an effective amount of IGnT or a biologically active fragment thereof or a pharmaceutical composition containing IGnT or the fragment.
  • an effective amount means an amount of the IGnT protein or peptide sufficient to induce the conversion of the i determinant on the linear polylactosaminoglycan to the I branched form or to inhibit the conversion of the i determinant on the linear polylactosaminoglycan to the I branched form.
  • an effective amount of IGnT or a pharmaceutical composition comprising IGnT is an amount that is useful for modifying the biological function mediated by the regulatory activity of IGnT in a biological material in vitro, in vivo or ex vivo.
  • biological material means a cell, a tissue, an organ and an organism as well as an extract prepared from a cell, a tissue and an organ. If the method is practiced in vitro, contact with the biological material is effected by incubating the material with the IGnT. The ex vivo method is similar but includes the additional step of reintroducing the treated material into the subject.
  • the invention also provides a method of alleviating a pathologic condition caused by the conversion of a linear polylactosaminoglycan expressing i antigen into a branched structure that expresses I antigen comprising contacting a nucleic acid molecule encoding human IGnT or an active fragment thereof with an antisense oligonucleotide as disclosed above. Such contact prevents expression of human IGnT, which, in turn, prevents the conversion of a linear polylactosaminoglycan expressing i antigen into a branched structure that expresses I antigen.
  • a "pathologic condition" is a pathology arising as a result of human IGnT activity. Examples of such pathologic conditions include tumor cell adhesion to endothelium and leukocyte adhesion to inflammatory sites, which occur in association with the conversion of i antigen to I antigen.
  • the invention also provides a method of alleviating a pathologic condition caused by the underexpression of human IGnT comprising contacting the linear polylactosaminoglycan expressing i antigen with purified soluble human IGnT or an active fragment thereof. Upon contact, the linear polylactosaminoglycan, which expresses i antigen, binds with IGnT and is converted into a branched structure, which expresses I antigen.
  • the term "pathologic condition" also encompasses a pathology arising from the underexpression of IGnT.
  • the i antigen is expressed on erythrocytes of the fetus and neonate and is subsequently converted by IGnT into I antigen, which is crucial for organ development. Frequently, however, IGnT is underexpressed, resulting in fewer conversions of i antigen to the I branched form, a condition which increases the patient's susceptibility to Type II hypersensitivity reactions. Examples of such reactions include hemolytic disease of the newborn, autoimmune hemolytic anemias and thrombocytopenias.
  • the invention also provides a method of detecting the presence of linear polylactosaminoglycans expressing i antigen on the cell surface comprising contacting a sample of cells with IGnT or an active fragment thereof and detecting binding of IGnT or the fragment to the cell surface i antigenic determinant. The presence of such binding indicates the presence of the linear polylactosaminoglycan expressing i antigen.
  • This example illustrates the construction of stably transfected CHO cells useful for identifying the transient expression of a nucleic acid molecule encoding IGnT.
  • CHO-Py-leu A cloned CHO cell line, designated CHO-Py-leu, was used for transient expression cloning (Seed and Aruffo, Proc. Natl. Acad. Sci.. USA, 84:3365-3369 (1987), which is incorporated herein by reference) . Sasaki et al., J. Biol. Chem.. 262:12059-12076 (1987), and Smith et al., J. Biol. Chem.. 265:6225-6234 (1990), each of which is incorporated herein by reference) have reported that CHO cells express the linear i-antigen.
  • pPSVEI-PyE which contains the polyoma virus early genes (Muller et al., Mol. Cell. Biol.. 4:2406-2412 (1984), which is incorporated herein by reference)
  • pZIPneo-leu which contains leukosialin (CD43) and neomycin cDNA
  • CHO cell lines expressing polyomavirus large T antigen and human leukosialin were established by cotransfecting CHODG44 cells with pPSVEI-PyE and pZIPneo- leu, followed by selection of cells expressing G418 resistance.
  • Polyoma virus large T antigen-mediated replication of plasmids in these cell lines was assessed by measurement of the methylation status of the recombinant DNA (Heffernan and Dennis, Nucl. Acids. Res.. 19:85-92 (1991), which is incorporated herein by reference) using pcDNAI harboring cDNA encoding galactosyltransferase (Aoki et al., Proc. Natl. Acad. Sci.. USA . 89:4319-4323 (1992), which is incorporated herein by reference) .
  • This example demonstrates the use of CHO-Py-leu cells to identify and allow the isolation of a vector containing a nucleic acid insert coding for IGnT.
  • pcDNAI-PA-I A cDNA library, pcDNAI-PA-I, was constructed essentially as described by Bierhuizen and Fukuda, 1992. Briefly, poly (A) + RNA was isolated from human PA-1 teratocarcinoma cells, which express a large amount of I branched structures in its polylactosaminoglycans (Fukuda et al., 1985), reverse transcribed and inserted into the mammalian expression vector pcDNAI (Invitrogen, San Diego, CA) .
  • Plasmid DNA was transfected into CHO-Py-leu cells using lipofection. After a 64 hour expression period, cells were detached at 37°C in PBS/5mM EDTA, pH7.4, pooled, centrifuged and resuspended in cold PBS, containing lOmM EDTA, 10% fetal calf serum, pH 7.4, and human anti-I antibodies (Step) as serum in 1:100 dilution. After 1 hour incubation on ice, the cells were washed and panned on dishes coated with goat anti-human IgM (Sigma, St. Louis, MO) as described by Wysocki and Sato, Proc. Natl. Acad. Sci.. USA . 75:2844-2848 (1978), which is incorporated herein by reference) .
  • goat anti-human IgM Sigma, St. Louis, MO
  • Plasmid DNA was rescued from transfected CHO- Py-leu cells that adhered to the panning dishes and digested with Dpnl to remove plasmids that were not replicated in transfected cells. Plasmids that remained intact were transformed into the host E. coli MC1061/P3 cells (Seed and Aruffo, 1987). Following this round of transformation, plasmid DNA was prepared and used for an additional round of screening by the same procedure. E. coli transformants isolated from this second enrichment were plated to yield four pools of approximately 2,000 colonies each.
  • Plasmid DNA was prepared from each plate and transfected separately into CHO-Py-leu cells, after which the transfected cells were screened by panning as described above. One of the plasmid pools yielded relatively more attached and partially agglutinated cells. Transformants corresponding to this group were plated again to yield eight pools of approximately 500 colonies each and replica plates were made. Plasmid DNA was prepared from the replica plates, transfected separately into CHO-Py-leu cells and transfectants were screened for the expression of the I antigen by immunofluorescence (see below). One of the plasmid pools was selected and, following three subsequent rounds of sib selection with sequentially smaller active pools, a single plasmid, pcDNAI-IGnT, that directed the expression of the I antigen at the cell surface was isolated.
  • This example provides the methodology used to identify transfected cells expressing a protein having the activity of IGnT.
  • transfected cells were fixed with 0.05% p-formaldehyde in PBS and stained with a 1:100 dilution of serum containing human anti-I antibody (Ma or Step) , followed by fluorescein-conjugated goat anti-human IgM (Sigma, St. Louis, MO) in order to identify the transient expression of I antigen.
  • the cells were examined under a Zeiss
  • CHODG44 cells were transfected either with pSV2neo, alone, or with pSV2neo and pcDNAI-IGnT using a calcium phosphate method (Graham and Van der Eb, Virology. 52:456-467 (1973), which is incorporated herein by reference) and grown in the presence of G418 in order to select stable transfectants. Following G418 selection, clonal cell lines were isolated by limiting dilution to obtain CHO-neo and CHO-neo-IGnT cell lines, respectively. CHO-neo-IGnT cells were observed to express the I antigen recognized by human anti-I antibody (Ma) , whereas CHO-neo cells showed no staining (not shown) .
  • Ma human anti-I antibody
  • This example provides the methodology for determining the sequence of the nucleic acid molecule encoding a protein having the activity of IGnT and for deducing the amino acid sequence of the protein, which was compared with previously reported protein sequences.
  • the cDNA insert present in pcDNAI-IGnT was sequenced using the dideoxy chain-termination method
  • Oligonucleotide primers were synthesized according to the flanking sequences present in the plasmid. The nucleic acid sequence was extended by using oligonucleotide primers synthesized according to the nucleic acid sequence determined for the cDNA insert.
  • the 1807 base pair cDNA insert contains a single open reading frame in the sense orientation with respect to the pcDNAI promoter ( Figure 6).
  • the predicted reading frame encodes a 400 amino acid protein having a calculated molecular mass of 45,860 daltons. Based on hydropathy analysis, the protein was determined to have a type II transmembrane topology, which is characteristic of all mammalian glycosyltransferases cloned to date (see Paulson and Colley, 1989; Schachter, 1991; Joziasse, 1992).
  • the type II transmembrane topology contains a very short cytoplasmic NH 2 -terminal segment of six amino acid residues, followed by a 19-amino acid transmembrane domain that is flanked by basic amino acid residues.
  • the COOH-terminal sequence which presumably consists of the stem and catalytic domains is large and likely resides in the lumen of the Golgi complex.
  • a consensus polyadenylation signal sequence was not found in the 3'- flanking sequence, suggesting that during construction of the library, cDNA synthesis was initiated at an A-rich sequence (nucleotides 1537-1547, see Figure 6), rather than at the poly A tail.
  • This example demonstrates the expression of mRNA encoding IGnT in PA-1 cells and identifies the mRNA as a 4.4 kb transcript.
  • RNA was prepared using a commercial RNA purification kit (Stratagene, La Jolla, CA) , resolved by electrophoresis in a 1.2% agarose-2.2 M formaldehyde gel and transferred onto a nylon membrane (Micro Separations Inc., MA) (Sambrook et al., 1989).
  • the nucleic acid sequence encoding the putative catalytic domain of IGnT was amplified using PCR (Saiki et al.
  • This example provides an analysis of the genomic DNA sequences encoding IGnT and C2GnT and suggests the existence of one or more other members of a family of glycosyltransferases, which includes IGnT and C2GnT.
  • Genomic DNA was analyzed by Southern blot hybridization using IGnT- and C2GnT-specific nucleic acid sequences as probes. Genomic DNA was prepared from HL-60 cells as described (Sambrook et al. 1989) and subjected to Southern blotting and hybridization as described previously (Siebert and Fukuda, J. Biol. Chem.. 261: 12433-12436 (1986), which is incorporated herein by reference) .
  • the blots were hybridized with cDNA probes in 6X SSPE, 0.5%SDS, 50 ⁇ g/ml denatured, sheared salmon sperm DNA containing 50% formamide at 42°C for several hours, then washed in 2X SSPE/0.5%SDS at room temperature for several hours.
  • the IGnT probe was prepared as described for northern blot analysis.
  • the putative catalytic domain of C2GnT also was amplified by PCR as described by Bierhuizen and Fukuda, 1992, and labeled using a random priming method.
  • Hindlll fragments represent the coding sequence for C2GnT and the IGnT, respectively ( Figure 9).
  • the two sequences cross-hybridized with the cDNA probes under the low stringency conditions (data not shown) .
  • Several genomic fragments hybridized with one cDNA probe but not the other.
  • a Hindlll fragment of approximately 16 kb and a Xbal fragment of approximately 12 kb were detected by the IGnT probe but not the C2GnT probe.
  • Xbal digestion yielded at least four fragments that were detected by both probes, even though there is no Xbal restriction site in either of the cDNA sequences.
  • This example provides a method for examining the structure of the IGnT and C2GnT genes in HL-60 cell genomic DNA.
  • genomic sequences coding for the two enzymes were examined.
  • the sequences were amplified by PCR using genomic DNA as HL-60 cell genomic DNA as template.
  • the 5' and 3' primers were synthesized according to the 5' and 3' flanking sequences of the IGnT and C2GnT cDNA sequences.
  • the 5' and 3' primers for amplification of the IGnT gene start at position -154 with respect to the translation initiation site and at a position 232 nucleotides after the stop codon, respectively.
  • the 5' and 3' primers for amplification of the C2GnT gene start at position -125 with respect to the translation initiation site and at a position 141 nucleotides after the stop codon, respectively.
  • Amplification of genomic DNA was repeated 35 times as follows: denaturation for 1 min at 94°C, annealing for 2 min at 55°C and polymerization for 5 min at 68°C.
  • the PCR products were subjected to 1.0% agarose gel electrophoresis.
  • the amplification products have the size expected for cDNA sequences of 1589 bp (IGnT) and 1553 bp (C2GnT).
  • This example demonstrates that cells expressing the cloned IGnT nucleic acid molecule acquire the ability to convert i antigen to I antigen.
  • CHO cells were stably transfected with pcDNAI-IGnT and pSV2neo or with pSV2neo, alone. Following G418 selection, clonal cell lines were isolated by limiting dilution to obtain CHO-neo-IGnT and CHO-neo cell lines, respectively.
  • CHO-neo-IGnT cells and the control CHO-neo cells were metabolically labeled for 24 hours with [ 3 H]- galactose (lO ⁇ Ci/ml) in ⁇ -MEM supplemented with 10% fetal calf serum. Labeled cells were harvested using a rubber policeman, washed with PBS and collected by centrifugation. The cell pellets were extracted with ten volumes of chloroform-methanol (2:1, v/v) as described by Fukuda et al. (1985) and the cell residues were digested with pronase for 24 hours at 60°C in a toluene atmosphere. Following pronase digestion, the samples were boiled for 10 minutes to denature any remaining enzyme.
  • Figure 11 demonstrates that CHO-neo-IGnT cells produced more glycopeptides having higher molecular weights than were produced by the CHO-neo cells.
  • glycopeptides were digested with endo- ⁇ - galactosidase, glycopeptides from CHO-neo-IGnT cells were more resistant to the enzyme treatment and yielded much less disaccharide, GlcNAc ⁇ l—>3Gal ( Figure 11), which can be produced only from a linear polylactosaminoglycan chain that contains at least three N-acetyllactosamine repeats (see Fukuda et al., J. Biol. Chem..
  • glycopeptides obtained from the [ 3 H]- galactose labeled CHO-neo and CHO-neo-IGnT cells were purified as described in Example IX and methylated as described by Ciucanus and Kerek, Carbohvdr. Res.. 131:209-217 (1984), which is incorporated herein by reference. Prior to methylation, non-radioactive glycopeptides prepared from fetuin (Sigma, St. Louis, MO) were added as a carrier.
  • the methylated glycopeptides were dissolved in chloroform, washed five times with water and dried under a nitrogen stream, then hydrolyzed in 3N HC1 for 3 hr at 80°C. After drying the hydrolysates under a nitrogen stream, the partially methylated galactose residues were dissolved in a small volume of chloroform-methanol (1:1, v/v) , applied to a silica gel G plate and subjected to thin layer chromatography in acetone:water:ammonium hydroxide (250:3:1.5, v/v/v) as described by Lee et al., 1990. Following chromatography, the sample lanes were separated into 0.5 cm sections and radioactivity was determined by liquid scintillation counting.
  • IGnT is located on human chromosome 9 at the same locus which contains C2GnT.
  • chromosomal localization of the genes encoding the glycosyltransferases was determined by in situ chromosome hybridization. In situ hybridization was performed on chromosome preparations obtained from human lymphocytes cultured in the presence of phytohemagglutinin for 72 hours. The conditions for labeling the probes, hybridization and washing were as described by Nguyen et al., J. Cell. Biol.. 102:711-715 (1986), which is incorporated herein by reference.

Abstract

La présente invention concerne une molécule d'acide nucléique codant à la fois les formes solubles et les formes liées à l'enveloppe de l'acétylglucosaminyltransférase, l'enzyme ramifiante-I (IGnT). On décrit également des vecteurs contenant la molécule d'acide nucléique isolée codant l'IGnT humaine ainsi que les cellules hôtes de recombinaison transformées à l'aide de vecteurs. De plus, l'invention se rapporte à un procédé de préparation d'une forme liée de l'IGnT humaine et à des procédés de préparation et de purification de l'IGnT humaine soluble et des fragments actifs de chaque forme. On décrit également des oligonucléotides anti-sens complémentaires à une molécule d'acide nucléique codant une IGnT humaine ou bien un fragment actif de celle-ci, des anticorps dirigés contre l'IGnT humaine, des compositions pharmaceutiques apparentées à l'IGnT humaine et des mammifères non humains transgéniques exprimant de l'ADN codant une IGnT humaine normale ou mutante. On décrit encore des procédés de régulation de l'expression de l'IGnT et des procédés de modification d'une fonction biologique induite par l'activité régulatrice de l'IGnT. De plus, on décrit des procédés de détection de la présence de polylactosaminoglycanes exprimant des déterminants antigéniques sur la surface d'une cellule.
PCT/US1993/008476 1993-09-09 1993-09-09 EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE WO1995007020A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US1993/008476 WO1995007020A1 (fr) 1993-09-09 1993-09-09 EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1993/008476 WO1995007020A1 (fr) 1993-09-09 1993-09-09 EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE

Publications (1)

Publication Number Publication Date
WO1995007020A1 true WO1995007020A1 (fr) 1995-03-16

Family

ID=22236931

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008476 WO1995007020A1 (fr) 1993-09-09 1993-09-09 EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE

Country Status (1)

Country Link
WO (1) WO1995007020A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014535A2 (fr) * 1999-08-24 2001-03-01 Glycozym Aps UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc - GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
WO2003057868A1 (fr) * 2001-12-28 2003-07-17 National Institute Of Advanced Industrial Science And Technology N-acetylglucosamines transferase et acides nucleiques la codant
US6995004B2 (en) 1998-12-04 2006-02-07 Glycozym Aps UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β 1,3-N-ACETYLGALACTOSAMINE-α-R / N-ACETYLGLUCOSAMINE-β 1,3,-N-ACETYLGALACTOSAMINE-α-R (GLCNAC TO GALNAC) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2/4GNT
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
US9328170B2 (en) 2011-05-25 2016-05-03 Merck Sharp & Dohme Corp. Method for preparing Fc containing polypeptides having improved properties

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS, Volume 163, No. 1, issued October 1983, J. ZIELENSKI et al., "Sera of I Subjects Have the Capacity to Synthesize the Branched G1cNAc-beta-1,6-ÄG1cNAc(beta-1,3)ÜGa1...Structure", pages 114-118. *
GENES & DEVELOPMENT, Volume 7, No. 3, issued 10 March 1993, M.F.A. BIERHUIZEN et al., "Expression of the Developmental-I Antigen by a Cloned Human cDNA Encoding a Member of a beta-1,6-N-Acetylglucosaminyltransferase Gene Family", pages 468-478. *
JAPANESE JOURNAL OF CANCER RESEARCH, Volume 83, issued August 1992, J. GU et al., "Deficiency of beta-1-6 N-Acetylglucosaminyltransferase Involved in the Biosynthesis of Blood Group I Antigen in the Liver of LEC Rats", pages 878-884. *
JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 259, No. 21, issued 10 November 1984, F. PILLER et al., "Biosynthesis of Blood Group I Antigens", pages 13385-13390. *
PROC. NATL. ACAD. SCI. U.S.A., Volume 89, No. 19, issued October 1992, M.F.A. BIERHUIZEN et al., "Expression Cloning of a cDNA Encoding UDP-G1cNAc:Ga1-beta-1-3-Ga1NAc-R (G1cNAc to Ga1NAc) beta-1-6G1cNAc Transferase by Gene Transfer into CHO Cells Expressing Polyoma Large Tumor Antigen", pages 9326-9330. *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995004B2 (en) 1998-12-04 2006-02-07 Glycozym Aps UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β 1,3-N-ACETYLGALACTOSAMINE-α-R / N-ACETYLGLUCOSAMINE-β 1,3,-N-ACETYLGALACTOSAMINE-α-R (GLCNAC TO GALNAC) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2/4GNT
WO2001014535A2 (fr) * 1999-08-24 2001-03-01 Glycozym Aps UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc - GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
WO2001014535A3 (fr) * 1999-08-24 2001-06-21 Tilo Schwientek UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc - GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3
AU775990B2 (en) * 1999-08-24 2004-08-19 Glycozym Aps UDP-n-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R/(GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
US6794169B2 (en) 1999-08-24 2004-09-21 Glycozym Aps UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R / (GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3
WO2003057868A1 (fr) * 2001-12-28 2003-07-17 National Institute Of Advanced Industrial Science And Technology N-acetylglucosamines transferase et acides nucleiques la codant
US9187552B2 (en) 2010-05-27 2015-11-17 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
US10858686B2 (en) 2010-05-27 2020-12-08 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
US11959118B2 (en) 2010-05-27 2024-04-16 Merck Sharp & Dohme Llc Fc-containing polypeptides having improved properties and comprising mutations at positions 243 and 264 of the Fc-region
US9328170B2 (en) 2011-05-25 2016-05-03 Merck Sharp & Dohme Corp. Method for preparing Fc containing polypeptides having improved properties

Similar Documents

Publication Publication Date Title
US5766910A (en) Expression of the developmental I antigen by a cloned human cDNA encoding a member of a beta-1, 6-N-acetylglucosaminyltransfrase gene family
AU706747B2 (en) Antibody specific for beta1->6N- acetylglucosamininyltransferase
Bierhuizen et al. Expression of the developmental I antigen by a cloned human cDNA encoding a member of a beta-1, 6-N-acetylglucosaminyltransferase gene family.
Koszdin et al. The cloning and expression of a human α-1, 3 fucosyltransferase capable of forming the E-selectin ligand
Nakayama et al. Expression cloning of a human GT3 synthase: GD3 and GT3 are synthesized by a single enzyme
JPH11512921A (ja) フコシルトランスフェラーゼ遺伝子およびその使用
CA2322779A1 (fr) Glycosylsulfotransferase-3
US20090269802A1 (en) Alpha 1,4-galactosyltransferase and dna encoding thereof
JPH10504707A (ja) 異種移植片の超急性拒否反応を減少させる方法
Hiroi et al. Molecular cloning of human homolog of yeast GAA1 which is required for attachment of glycosylphosphatidylinositols to proteins 1
CA2114631C (fr) Sequences de codage de la n-acetylglucosaminyltransferase v
JP2001504685A (ja) 糖質エピトープ低減用の改良された核酸
WO1995007020A1 (fr) EXPRESSION DE L'ANTIGENE I DE DEVELOPPEMENT PAR UN ADNc CODANT UNE BETA-1,6-N-ACETYLGLUCOSAMINYLTRANFERASE
US5849904A (en) Isolated nucleic acid molecules which hybridize to polysialyl transferases
AU779689B2 (en) Human poly(ADP-ribose) polymerase 2 materials and methods
US5747326A (en) Isolated nucleic acid molecules which encode mammalian α2,8 polysialyl transferases
US20030190739A1 (en) Tankyrase2 materials and methods
AU692355B2 (en) Isolated polysialyl transferases, nucleic acid molecules coding therefor, methods of production and use
AU758143B2 (en) UDP-N- acetyl glucosamine: galactose-beta1, 3-N- acetyl galactosamine- alpha-R/ N- acetyl glucosamine -beta1, 3-N- acetyl galactosamine- alpha-R (GlcNAc to GalNAc) beta1,6-N- acetyl glucosaminyl transferase, C2/4GnT
AU770407B2 (en) N-acetylglycosaminyl transferase genes
WO2002081688A1 (fr) Molecules d'adn codant pour la synthase d'igb3, et ses utilisations pour l'interruption des genes de glycosyltransferase dans des tissus et organes de xenogreffe
WO1996011212A1 (fr) Nouveau ligand de tyrosine kinase de type recepteur
AU2616502A (en) Methods for reducing hyperacute rejection of xenografts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA